Send to

Choose Destination
J Acquir Immune Defic Syndr. 2014 Jan 1;65(1):87-90. doi: 10.1097/QAI.0b013e3182a97b81.

Performance of 3 rapid tests for discrimination between HIV-1 and HIV-2 in Guinea-Bissau, West Africa.

Author information

*Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark; †Bandim Health Project, Indepth Network, Bissau, Guinea-Bissau; ‡National HIV Programme, Ministry of Health, Bissau, Guinea-Bissau; §National Public Health Laboratory, Bissau, Guinea-Bissau; ‖GloHAU, Center for Global Health, School of Public Health, Aarhus University, Aarhus, Denmark; and ¶Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark.


As HIV-2 is intrinsically resistant to nonnucleoside reverse transcriptase inhibitors, it is mandatory to discriminate between HIV types before initiating antiretroviral treatment. Guinea-Bissau has the world's highest prevalence of HIV-2 and HIV-1/HIV-2 dually infected individuals. We evaluated 3 rapid tests for discrimination between HIV-1, HIV-2, and dual infections among 219 patients from Guinea-Bissau by comparing with the gold standard (INNO-LIA). Genie III HIV-1/HIV-2 was the best performer with regard to discriminatory capacity (agreement 91.8%), followed by Immunoflow HIV1-HIV2 (agreement 90.9%) and SD Bioline HIV-1/2 3.0 (agreement 84.5%). Our results underscore the need for evaluation of tests in relevant populations before implementation.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center